ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4000 participants.

Also called NCT06320431

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06320431
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06320431. Randomized; single masking; primary purpose treatment. Start 2024-09-26 (actual); primary completion 2030-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Acronym
ACT-WHEN
Condition
Acute Ischemic Stroke AIS
Condition
Stroke Acute
Condition
Stroke, Acute, Stroke Ischemic
Intervention (Drug)
Tenecteplase
Lead sponsor
University of Calgary (class: other)
Collaborator
The George Institute for Global Health, Australia (class: other)

Record details

Record id
cardio:ct-nct06320431
Content hash
209162d3933682ff1d7105983388786f5eecd9feb4164fad1d8832ec81db6a4a